Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel
Evid Based Med. 2011 Aug;16(4):124-5.
doi: 10.1136/ebm1203.
Epub 2011 Jun 24.